NasdaqGS · Biotechnology

Madrigal Pharmaceuticals (MDGL)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+31.2%

$678.06 average target

$516.74-2.35 (-0.5%)Latest market snapshot · Yahoo Finance

Market cap$11.94B

Cash$838.8M

Quarterly burn$23.3M

Pipeline assets3

Short float10.0%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

The average target implies 31.2% upsideTargets are estimates—not guarantees—and can change after company updates.

$678.06Average target

Wall Street consensus

Strong BuyBased on 16 analyst opinions

17ratings

Buy 16Hold 1Sell 0

Price-target range

$678.06

+31.2%

Low $543.00High $962.00

CurrentAverage

Bear case$543.00+5.1%

Base case$678.06+31.2%

Bull case$962.00+86.2%

Analyst coverage16published opinions

Bullish share94%buy recommendations

Target spread$419low-to-high dispersion

Consensus score1.31.0 is strongest

Recommendation mix

Current rating breakdown

Company profile

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.